Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.

15:54 09/01/2025

Hengrui Medicine (600276.SH) announced that the company has received a "Notice of Acceptance" issued by the National Medical Products Administration...

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.

New Stock News | V-Shi Technology submits application to Hong Kong Stock Exchange. The company's products have been widely used in multiple basic industrial fields.

New stock news | Lu Peng Pharmaceuticals submitted an application to the Hong Kong Stock Exchange. Its core product LP-168 is the world's first and only "covalent non-covalent" dual BTK inhibitor.

New Stock News: Suzhou Tiantong Weishi Electronic Filed for Listing on Hong Kong Stock Exchange, with Smart Driving Solutions covering L2-L2+ and L4 levels of automation.

New Stock News | V-Shi Technology submits application to Hong Kong Stock Exchange. The company's products have been widely used in multiple basic industrial fields.

New stock news | Lu Peng Pharmaceuticals submitted an application to the Hong Kong Stock Exchange. Its core product LP-168 is the world's first and only "covalent non-covalent" dual BTK inhibitor.

New Stock News: Suzhou Tiantong Weishi Electronic Filed for Listing on Hong Kong Stock Exchange, with Smart Driving Solutions covering L2-L2+ and L4 levels of automation.